FDA approves Eylea 12-week dosing for wet AMD

FDA authorizes Eylea 12-week dosing for wet AMD (AGE-RELATED MACULAR DEGENERATION)

FDA authorizes Eylea 12-week dosing for wet AMD (AGE-RELATED MACULAR DEGENERATION)

The FDA has actually approved a supplemental biologics certify application for a 12-week application routine of Eylea injection shot in damp age-related macular deterioration patients The FDA formerly released a complete feedback letter to Regeneron relating to the sBLA, which is based on information from the stage 3 VIEW 1 as well as 2 trials, in which Wet AMD patients obtained Eylea (aflibercept) shots a minimum of every 12 weeks, with additional dosages as needed.

Khanna Institute Of Lasik
Khanna Institute Of Lasik



“We are happy  that the FDA has accepted an upgraded tag for Eylea,” George D. Yancopoulos, MD, PhD, president and also CSO at Regeneron, claimed in the launch release. “Offering information to retinal doctors about the visual results with a modified 12-week dosing timetable will assist medical professionals make one of the most educated selections in dealing with patients experiencing wet age-related macular deterioration or Wet AMD.”

Testimonial From Brenda Song, Beverly Hills Lasik Patient


Eylea was currently authorized for application intervals of every 4 weeks or every 8 weeks, after three first regular monthly dosages, for wet AMD.

Pterygium

Epidemiology
Global Information
 The occurrence of pterygium was discovered to be 10.2% worldwide, with highest
possible prevalence in reduced altitude regions.
 Increased incidence of pterygium is noted in the tropics as well as in an equatorial
zone in between 30 ° north as well as southern latitudes, Liu et al, 2013.
 Higher occurrence is related to persistent sunlight exposure (ultraviolet light), older
age, male sex, as well as exterior activity, Liu et alia, 2013.
Regional Info (Latin America)
 One study amongst a Latino population in Tucson Arizona, USA found the frequency
of pterygium to be 16%, West et al, 2009.
 A hospital-based research in Lima, Peru, reported the prevalence of pterygium to be
31%, with a considerable rise in occurrence with enhancing age, Rojas et al, 1986.
 In a population-based example in Botucatu City, Sao Paulo State, Brazil, the reported
occurrence was 8.12%, impacting primarily 40-50 year old men, Shiratori et al, 2010.
Differential diagnosis
Pseudopterygium

Pseudopterygium
Pseudopterygium
Pseudopterygium
Pseudopterygium
Pingeucula
Pingeucula
Pannus Episcleritis, sclerokeratitis
Pannus Episcleritis, sclerokeratitis
Conjunctival intraepithelial
 neoplasia. A. Papilliform. B. Gelatinous. C. Leukoplakic
 Conjunctival and corneal intraepithelial tumor (CIN)
Conjunctival intraepithelial
neoplasia. A. Papilliform. B. Gelatinous. C. Leukoplakic
Conjunctival and corneal intraepithelial tumor (CIN)
Limbal dermoid
Limbal dermoid


Interpretation
 Pterygium originates from the Greek word meaning wing, pterygos.
 Pterygium is a triangular fibrovascular growth that expands from the conjunctiva
towards the cornea.
 It is much more typical in the interpalpebral fissure area as well as might occur
occasionasally or temporally or both. The nasal location is much more typical.

 Although the pathophysiology is not clearly comprehended, ultraviolet (UV) light is
recognized as one of the most essential danger elements.
 UV light forms complimentary radicals that cause damages in DNA, RNA, and also
the extra celluar matrix of cells.
 Ultraviolet-B (UVB) causes expression of cytokines as well as growth factors in
pterygial epithelial cells.
 Polymorphisms of the DNA break repair fixing genetics Ku70 have actually been
connected with hereditary predisposition to pterygia growth.
 Increased levels of T-cells as well as inflammatory markers have actually additionally
been kept in mind in pterygial cells contrasted to regular conjunctival cells.
Risk Elements
 Ultraviolet direct exposure solitary most substantial risk element.
 Exposure to irritants (dirt, sand, wind).
 Inflammation.
 Dry eye surface.


Symptoms

Slit-lamp image of a pterygium.

Slit-lamp image of a pterygium.
 Wedge-shaped, transparent membrane layer with apex prolonging onto cornea.
 White to pink in color, depending upon vascularity.
 Vascular straightening towards the progressing head of the pterygium.

Stocker line (arrow)

Stocker line: iron line on cornea at leading side of pterygium.
 Regular or irregular astigmatism
 Degenerative changes such as cystic changes.
 May be asymptomatic.
 Redness.
 Irritation.
 Decreased vision.
Medical diagnosis
 Diagnosis is made scientifically based upon slit-lamp evaluation and also typical
appearance of the lesion.
Management

Immediate postoperative photograph showing a suture conjunctival autograft after pterygium
 excision.
Immediate postoperative photograph showing a suture conjunctival autograft after pterygium
excision.

Scleral dellen.
Scleral dellen.

Prevention
 Wearing eye protection, sunglasses, safety glasses, and/or an overflowed that is
suggested when one is exposed to sunlight or dirt. Sunglasses that obstruct 99%–
100% of both UVA as well as UVB rays are preferred.
Medical Monitoring.
 Small pterygia without aesthetic impairment can be dealt with symptomatically with
artificial tears as well as eye lubricants.
 Clinical therapy (man-made tears and lubricants) does not reduce progression or
cause regression of pterygia.
 In patients with irritative signs and symptoms, preservative-free man-made tears are
suggested for moderate inflammation as well as topical steroids are advised for
modest inflammation.
 Monitoring pterygia at 6– 12 months is practical.
Surgical Monitoring
Surgical removal is taken into consideration for the following problems:
 Decrease in aesthetic acuity because of astigmatism or infringement onto aesthetic
axis.
 A cosmetically significant pterygium.
 When it interferes with contact lens wear.
 Symptomatic degenerative changes like cystic changes.
 Restrict